Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The US Food and Drug Administration (FDA) has recently licensed a form of ketamine – esketamine – as a treatment for depression which is resistant to other treatments. It is administered as a nasal spray in a clinic, initially twice a week, then weekly or fortnightly. Regular doses of the drug are necessary to prevent relapse.

image shows hand holding a nasal spray which administers the drug.

In the US, patients who start esketamine ($600 a dose) are asked about whether they have previously taken ketamine ($10 a dose), but not the other way round.

Associate Professor Rupert McShane, University of Oxford, says,

"History teaches us just how important it is to track patients who switch from one potentially addictive drug to another. European and UK regulators urgently need to ensure that treatments with ketamine, and other potentially addictive drugs, are all tracked in the same system along with esketamine. This same logic applies to people who are self-treating without a prescription. This sensible precaution would help prevent esketamine from suffering the same fate as benzodiazepines: overuse, backlash and stigma."

 

Patients' experiences matter – this sort of data platform will give them a voice.Associate Professor Rupert McShane.

 

Read the full article authored by Rupert McShane and Adam Winstock.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Kam Bhui joins MQ Science Council

Professor Kam Bhui appointed to MQ’s Science Council, a group of global experts who guide MQ’s research.

Experts hold first meeting for new international project on depression, anxiety and psychosis

The Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis, or GALENOS project, has launched in central London.

Ensuring LGBTQI+ people are treated fairly in mental health data

Andrey Kormilitzin outlines a new participatory study aimed at improving AI to take account of LGBTQI+ people so that their needs are better met by mental health services.

Friendship and mental health in adolescents

Tanya Manchanda's new paper investigates the role of friendship on the mental health outcomes of adolescents

Major wellbeing survey for 9-18 year olds launched

Researchers at Oxford are encouraging schools and colleges in four areas of the country to sign up to be part of the OxWell Student Survey.

‘Thinking Family’ when an adult has a serious illness

New research shows that although patient’s family details were often recorded, this information was not routinely used to help patients share their diagnosis with children.